drugset / Trial / NCT05566041
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
Phase 3
Active not recruiting
292 enrolled
EpicentRx, Inc.
Sciclone Pharmaceuticals (China) Co., Ltd. · collab
RandomizedCrossoverOpen-labelTreatment
Summary
This Global Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.
Timeline
- Start
- 2022-08-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NIBROZETONE | Other / unclassified | 4 mg | Intravenous |
| Comparator | Carboplatin | Small molecule | 5 unknown | — |
| Comparator | Cisplatin | Other / unclassified | 60 mg/m2 | — |
| Comparator | Etoposide | Small molecule | 100 mg/m2 | — |